cor2ed
engage checkpoint medical linkedin twitter
bg

Update on key HCC data presented at ASCO GI and EASL-LCS 2022

Update on key HCC data presented at ASCO GI and EASL-LCS 2022

Prof. James Harding

Professor James Harding provides insights on key topics and abstracts in HCC presented at ASCO GI and EASL-LCS 2022.
Portrait of James Harding
Prof. James Harding

Medical Oncologist

Memorial Sloan Kettering Cancer Center

United States (US)

preview next

time Podcast | open 15 min

Subscribe to our podcast series on:

download resources

I agree that this educational programme:

Was valuable to me:

1/3

Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimem, respectively

Other programmes of interest